Success Metrics

Clinical Success Rate
94.4%

Based on 17 completed trials

Completion Rate
94%(17/18)
Active Trials
5(21%)
Results Posted
88%(15 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
1
4%
Ph phase_2
7
29%
Ph phase_3
11
46%
Ph phase_4
2
8%

Phase Distribution

1

Early Stage

7

Mid Stage

13

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
1(4.8%)
Phase 2Efficacy & side effects
7(33.3%)
Phase 3Large-scale testing
11(52.4%)
Phase 4Post-market surveillance
2(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.4%

17 of 18 finished

Non-Completion Rate

5.6%

1 ended early

Currently Active

5

trials recruiting

Total Trials

24

all time

Status Distribution
Active(6)
Completed(17)
Terminated(1)

Detailed Status

Completed17
Recruiting3
Active, not recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
5
Success Rate
94.4%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.8%)
Phase 27 (33.3%)
Phase 311 (52.4%)
Phase 42 (9.5%)

Trials by Status

not_yet_recruiting14%
terminated14%
recruiting313%
active_not_recruiting28%
completed1771%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT07444801

Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact

Recruiting
NCT05388760Phase 2

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

Active Not Recruiting
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT05958407Phase 3

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

Completed
NCT03358693

Molecular Signatures in Inflammatory Skin Disease

Recruiting
NCT03160885Phase 3

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

Completed
NCT03761537Phase 3

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

Completed
NCT03131648Phase 3

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Completed
NCT05194540Phase 3

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

Completed
NCT03363854Phase 3

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Completed
NCT03562377Phase 2

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Completed
NCT03526861Phase 3

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Completed
NCT03587805Phase 3

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Completed
NCT04587453Phase 3

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

Completed
NCT03556592Phase 1

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Completed
NCT05938478

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

Recruiting
NCT06773455Phase 4

Tralokinumab for Dupilumab Failures

Active Not Recruiting
NCT04556461Phase 2

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

Completed
NCT02684097Phase 2

A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

Completed
NCT02281357Phase 3

Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24